Epidermal growth factor receptor gene mutation status and its association with clinical characteristics and tumor markers in non‑small‑cell lung cancer patients in Northwest China

Abdurahman,Ablajan; Anwar,Jurat; Turghun,Abdugheni; Niyaz,Madiniyet; Zhang,Liwei; Awut,Idiris

doi:10.3892/mco.2015.564

Epidermal growth factor receptor gene mutation status and its association with clinical characteristics and tumor markers in non‑small‑cell lung cancer patients in Northwest China

Authors:
- Ablajan Abdurahman
- Jurat Anwar
- Abdugheni Turghun
- Madiniyet Niyaz
- Liwei Zhang
- Idiris Awut
View Affiliations

Affiliations: Department of Thoracic Surgery, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830054, P.R. China, Clinical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830054, P.R. China
Published online on: May 11, 2015 https://doi.org/10.3892/mco.2015.564
Pages: 847-850

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study was conducted to investigate the mutation status of epidermal growth factor receptor (EGFR) and its association with clinical characteristics and tumor markers in non‑small‑cell lung cancer (NSCLC) patients from the Xinjiang Uygur Autonomous Region in China. We enrolled 51 cases of NSCLC patients who received radical surgical treatment in the First Affiliated Hospital of Xinjiang Medical University. Quantitative polymerase chain reaction was applied to detect exons 18, 19, 20 and 21 of the EGFR gene in tumor tissues. Multiple tumor markers, including carcinoembryonic antigen (CEA), were assessed preoperatively. The EGFR‑positive rate was 49.02% (25/51), with a mutation rate of 8% (2/25) in exon 18, 52% (13/51) in exon 19, 40% (10/51) in exon 21 and no mutations in exon 20. The positive mutation rate in men and women was 37.5% (12/32) and 68.42%, respectively (13/19), with a statistically significantly higher rate in women (P<0.05). There were also statistically significant differences among adenocarcinoma, adenosquamous carcinoma and squamous cell carcinoma cases (P<0.05), while no statistically significant differences were observed in adenocarcinoma cases regarding degree of differentiation, lymph node metastasis and TNM stage (P>0.05). There was a statistically significant association between the EGFR gene mutation status and the preoperative serum CEA level (P<0.05). The mutation rate of the EGFR gene was 68.42% in female lung adenocarcinoma patients, which supports the application of targeted therapy in such cases. However, whether it is possible to obtain information regarding targeted therapy through measuring the level of serum CEA for NSCLC patients with unknown EGFR mutation status requires further investigation through related studies including a higher number of cases.

View Figures

View References

1	Li MN, Li X, He ZC and Zhang ZH: Association between gene mutations of epidermal growth factor receptor and clinicopathological characteristics of non-small cell lung cancers. J Clin Exp Pathol. 29:402–405. 2013.
2	da Cunha Santos G, Shepherd FA and Tsao MS: EGFR mutations and lung cancer. Annu Rev Pathol. 6:49–69. 2011. View Article : Google Scholar : PubMed/NCBI
3	Huang GH, Du J, Hou XH, et al: A clinical pathology study between the different differentiation of non-small cell lung cancer (NSCLC) and the mutation of EGFR gene. Mol Diagn Ther. 6:97–100. 2014.
4	Li H, Pan Y, Li Y, et al: Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Lung Cancer. 79:8–13. 2013. View Article : Google Scholar : PubMed/NCBI
5	Boch C, Kollmeier J, Roth A, Stephan-Falkenau S, Misch D, Grüning W, Bauer TT and Mairinger T: The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): Routine screening data for central Europe from a cohort study. BMJ Open. 3:1–6. 2013. View Article : Google Scholar
6	Liu N, Zhang K, Yan SX, et al: EGFR mutations are closely associated with gefitinib response in non-small cell lung cancer patients. Modern Oncology. 21:330–333. 2013.
7	Zhang YS, He YY, Li XF, et al: Clinical analysis of factors influencing EGFR mutation status in patients with non-small cell lung cancer. Tumor. 34:147–152. 2014.
8	Yu H, Huang X, Zhu Z, Hu Y, Ou W, Zhang L and Zhou N: Significance of combined detection of LunX mRNA and tumor markers in diagnosis of lung carcinoma. Chin J Cancer Res. 26:89–94. 2014.PubMed/NCBI
9	Wang WJ, Tao Z, Gu W and Sun LH: Clinical observations on the association between diagnosis of lung cancer and serum tumor markers in combination. Asian Pac J Cancer Prev. 14:4369–4371. 2013. View Article : Google Scholar : PubMed/NCBI
10	Cedrés S, Nuñez I, Longo M, Martinez P, Checa E, Torrejón D and Felip E: Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 12:172–179. 2011. View Article : Google Scholar : PubMed/NCBI
11	Zhou JX, Yang H, Deng Q, et al: Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages. Ann Oncol. 24:1319–1325. 2013. View Article : Google Scholar : PubMed/NCBI
12	Huang Q and Li DQ: Epidermal growth factor receptor and alveolar epithelial atypical adenomatous hyperplasia. Int J Pathol Clin Med. 32:84–87. 2012.
13	Schneider CP, Heigener D, Schott-von-Römer K, et al: Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: An analysis of patients from German centers in the TRUST study. J Thorac Oncol. 3:1446–1453. 2008. View Article : Google Scholar : PubMed/NCBI
14	Wang X, Shi SS, Ma HH, et al: Respective analysis of EGFR mutations in non-small cell lung cancer. Mil Med J Southeast China. 14:387–389. 2012.
15	Zhao J, Zhu Y, Zhang L, Yu YW and Zheng JM: Detection of epidermal growth factor receptor gene mutations and its clinical significance in non-small cell lung cancers. Chin J Pathol. 40:671–674. 2011.(In Chinese).
16	Sriuranpong V, Chantranuwat C, Huapai N, Chalermchai T, Leungtaweeboon K, Lertsanguansinchai P, Voravud N and Mutirangura A: High frequency of mutation of epidermal growth factor receptor in lung adenocarcinoma in Thailand. Cancer Lett. 239:292–297. 2006. View Article : Google Scholar : PubMed/NCBI
17	Kobayashi S, Canepa HM, Bailey AS, Nakayama S, Yamaguchi N, Goldstein MA, Huberman MS and Costa DB: Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 8:45–51. 2013. View Article : Google Scholar : PubMed/NCBI
18	Hata A, Yoshioka H, Fujita S, et al: Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer. J Thorac Oncol. 5:1524–1528. 2010. View Article : Google Scholar : PubMed/NCBI
19	van Zandwijk N, Mathy A, Boerrigter L, Ruijter H, Tielen I, de Jong D, Baas P, Burgers S and Nederlof P: EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: Retro- and prospective observations in non-small-cell lung cancer. Ann Oncol. 18:99–103. 2007. View Article : Google Scholar : PubMed/NCBI
20	Boldrini L, Alì G, Gisfredi S, et al: Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: A population-based prospective study. Oncol Rep. 22:683–691. 2009.PubMed/NCBI
21	Wu YL, Zhong WZ, Li LY, et al: Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: A meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol. 2:430–439. 2007. View Article : Google Scholar : PubMed/NCBI
22	Zhu CQ, da Cunha Santos G, Ding K, et al: National Cancer Institute of Canada Clinical Trials Group Study BR.21: Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 26:4268–4275. 2008. View Article : Google Scholar : PubMed/NCBI
23	Xu L, Zheng MF, Zhang J, Zhu XF, Chen R, Lu R, Wo B and Chen J: EGFR Mutations in correlation with the tumor markers in NSCLC patients. J Med Res. 40:79–81. 2011.
24	Shoji F, Yoshino I, Yano T, Kometani T, Ohba T, Kouso H, Takenaka T, Miura N, Okazaki H and Maehara Y: Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas. Cancer. 110:2793–2798. 2007. View Article : Google Scholar : PubMed/NCBI